摘要
目的探讨达格列净联用利格列汀在2型糖尿病合并早期糖尿病肾病中的临床治疗效果。方法选取2021年4月—2023年4月新会区人民医院收治的76例2型糖尿病合并早期糖尿病肾病患者为研究对象,根据治疗方法的不同分为两组,观察组(39例)应用达格列净联合利格列汀治疗,对照组(37例)应用格列齐特缓释片+盐酸二甲双胍缓释片治疗,治疗3个月后比较两组患者的空腹血糖、糖化血红蛋白、血肌酐、24 h尿微量白蛋白、肾小球滤过率及不良反应发生情况。结果治疗后,两组空腹血糖及糖化血红蛋白水平均低于治疗前,差异有统计学意义(P均<0.05)。治疗后,对照组空腹血糖水平低于观察组,差异有统计学意义(P<0.05)。对照组治疗后24 h尿微量白蛋白、血肌酐及肾小球滤过率与治疗前比较,差异无统计学意义(P均>0.05);而观察组治疗后24 h尿微量白蛋白较治疗前减少,血肌酐较治疗前下降,肾小球滤过率较治疗前升高,差异有统计学意义(P均<0.05)。两组患者均未发生严重不良反应。结论达格列净联用利格列汀2型糖尿病合并早期糖尿病肾病的治疗中既能良好控制血糖,也能使尿蛋白减少、改善肾功能。
Objective To investigate the clinical effect of dapagliflozin combined with linagliptin in the treatment of type 2 diabetes mellitus with early diabetic nephropathy.Methods A total of 76 patients with type 2 diabetes mellitus complicated with early diabetic nephropathy admitted to Xinhui District People's Hospital from April 2021 to April 2023 were selected as the study objects and divided into two groups according to different treatment methods.The ob-servation group(39 cases)was treated with dapagliflozin combined with linagliptin,and the control group(37 cases)was treated with gliclazide sustained-release tablets+metformin hydrochloride sustained-release tablets.After 3 months of treatment,fasting plasma glucose,glycated hemoglobin A1c,serum creatinine,24-hour urine microalbumin,glomerular filtration rate and incidence of adverse reactions were compared between the two groups.Results After treatment,the fasting plasma glucose and glycated hemoglobin A1c levels in the two groups were lower than those be-fore treatment,and the differences were statistically significant(both P<0.05).After treatment,the fasting plasma glucose level in the control group was lower than that in the observation group,and the difference was statistically sig-nificant(P<0.05).There were no significant differences in 24-hour urinary microalbumin,serum creatinine and glo-merular filtration rate in the control group before and after treatment(all P>0.05).In the observation group,24-hour urinary microalbumin after treatment was lower than that before treatment,serum creatinine was lower than that before treatment,and glomerular filtration rate was higher than that before treatment,the differences were statistically signifi-cant(all P<0.05).No serious adverse reactions occurred in the two groups.Conclusion Dapagliflozin combined with linagliptin in the treatment of type 2 diabetes mellitus complicated with early diabetic nephropathy can not only control blood glucose well,but also reduce urinary protein and improve renal function.
作者
林秀雯
LIN Xiuwen(Department of Endocrinology,Xinhui District People's Hospital,Jiangmen 529100,Guangdong,China)
出处
《糖尿病新世界》
2024年第11期26-29,共4页
Diabetes New World
基金
江门市科技计划项目(2021YL08031)。
关键词
达格列净
利格列汀
2型糖尿病
早期糖尿病肾病
Dapagliflozin
Linagliptin
Type 2 diabetes mellitus
Early diabetic nephropathy
